News

Doubly modified soya enters Europe
Enlarge image

BusinessEU

Doubly modified soya enters Europe

10.07.2012 - The European Commission has authorised the import of Monsanto’s soya which bears additional genes for a herbicide tolerance and an insecticide.

Just a few days after the European Food Safety Authority (EFSA) had approved the cultivation of genetically modified (GM) soya on European soils, the European Commission agreed on another soya matter. On 27 June, without public communication, the Commission authorised Monsanto Company’s genetically engineered soya Intacta RR2 Pro for import to the European Union. These soya plants harbour a combination of gene constructs that convey both tolerance for herbicides and resistance to insects. More specifically, Intacta is a combination of soys MON87701 and MON89788 which produce an insecticidal Bt protein and is tolerant to the herbicide glyphosate, respectively. It is the first time in the EU that gm-soya with stacked gene constructs has been allowed for usage in food and feed.

On 6 July the Brazilian Association of Seeds and Seedlings (ABRASEM) issued a statement „celebrating the opening of new doors to varieties of high technology seeds.“ Brazil is the main beneficiary of the authorisation as Monsanto’s soya is grown and harvested there. Europe is the second main destination of Brazilian soya exports, with China leading the chart. However, Intacta is not yet approved by China so that the European decision could very well be interpreted as trend-setting.

http://www.european-biotechnology-news.com/news/news/2012-03/doubly-modified-soy-enters-europe.html

M&AIreland

31.03.2015 In its aim to expand its drug portfolio in orphan disease products, Horizon Pharma has acquired US company Hyperion Therapeutics for US$1.1bn in cash. The takeover entitles the UK biopharma to all of Hyperion’s common stock.

BusinessGermany

31.03.2015 Merck Serono has forged a US$941m (€876m) deal with US Intrexon for the development and commercialisation of CAR-T therapies. The new CAR-T projects are set to strengthen their R&D technology portfolio in immuno-oncology.

Stock MarketsFranceEU

27.03.2015 Europe is once more proving that it can be a good bet for biotech companies going public. A newly established EU-wide lobbying initiative could help the IPO boom on its way.

FinancingPoland

24.03.2015 Poland has announced the closing of a new venture capital fund at US$42m (€32m). The fund, which is the first of its kind in Poland, is dedicated to the Life Sciences with a strong connection to Central and Eastern Europe.

BioeconomyFranceSwedenGermanyNetherlandsFinland

23.03.2015 A BASF-led consortium aims to decrease bio-based production costs using industrial biotechnology. The Horizon2020 funded consortium is the sixth project of the SPIRE Public Private Partnership and has a budget of €14m.

Stock MarketsFranceSwedenUKNorwayIreland

20.03.2015 There are no signs of inertia creeping into the European biotech industry this spring. A total of eight IPOs are set to go public by the end of the year’s first quarter.

FinancingUKEU

17.03.2015 Pharma giants GlaxoSmithKline (GSK) and Johnson & Johnson (J&J) will be key collaborators in a new global fund for dementia research to address the rising threat posed by dementia and Alzheimer’s disease.

FinancingFranceDenmarkSwedenGermany

19.03.2015 French venture capital firm Seventure Partners has raised a further €25m for its microbiome-focused Health for Life Capital Fund. It now stands at €100m.

EventsFranceEUSwitzerlandUKGermany

12.03.2015 With around 1,400 companies and 2,400 participants, the springtime counterpart of BIO-Europe enjoyed a successful premiere in France this year. The overall mood of the European biotech industry was positive, and the French hosts in particular reported new initiatives.

M&ABelgium

11.03.2015 Belgian cell-based therapeutics developer and CMO MaSTherCell SA has been acquired by US biotech Orgenesis Inc. for €23m.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • 4SC1.28 EUR10.34%
  • BASILEA110.70 CHF2.31%
  • BIOTEST98.10 EUR2.29%

FLOP

  • PAION2.36 EUR-6.72%
  • MOLOGEN5.45 EUR-4.22%
  • WILEX3.01 EUR-2.90%

TOP

  • CYTOS1.43 CHF297.2%
  • MEDIGENE12.31 EUR184.3%
  • FORMYCON26.94 EUR66.0%

FLOP

  • MORPHOSYS58.81 EUR-19.6%
  • BASILEA110.70 CHF-7.8%
  • WILEX3.01 EUR-4.4%

TOP

  • SANTHERA93.75 CHF2186.6%
  • FORMYCON26.94 EUR271.6%
  • WILEX3.01 EUR157.3%

FLOP

  • CYTOS1.43 CHF-53.1%
  • MOLOGEN5.45 EUR-52.6%
  • PAION2.36 EUR-35.7%

No liability assumed, Date: 01.04.2015